CyVek, Inc., a Wallingford, CT-based developer of multi-analyte immunoassay technology, secured a $5.5m Series D round of financing.
The round was led by Connecticut Innovations, with participation from a group of private investors.
The company intends to use funding to create the infrastructure needed to commercialize its novel immunoassay technology, currently in the beta testing phase.
Formed in 2010 and led by Per Hellsund, founder, President and CEO, CyVek develops CyPlex™, an integrated test system which includes a proprietary microfluidic cartridge that allows the analysis of multiple biomarkers from very small amounts of biological samples. The system, which has research and clinical applications, initially will be used in biomarker analysis in life sciences, drug discovery and clinical research.